Navigation Links
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
Date:1/6/2009

AMSTERDAM, January 6 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow transplantation, announces today the appointment of Dr. Maarten Egeler as Chief Medical Officer (CMO). Dr. Egeler is a global leading pediatric bone marrow transplantation physician and an internationally-recognized authority in pediatric hemato-oncology. He brings to Kiadis Pharma over more than 20 years of expertise in this field.

The appointment of Dr. Egeler is an important milestone in the development of Kiadis Pharma's lead product ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients. Dr. Egeler's appointment will strongly support the upcoming multi-center pivotal study on ATIR(TM) early 2009.

Dr. Egeler will join Kiadis Pharma part time next to his position as Head of the Pediatric Oncology and Bone Marrow Transplantation division of the University of Leiden. As Kiadis Pharma's CMO, he will oversee all medical affairs of the company and he will work closely with the company's global network of key opinion leaders in the transplantation community on the development of the company's products.

"Maarten has been acting as a medical advisor for Kiadis Pharma over the last year and we are very pleased that he agreed to become our CMO", says Manja Bouman, CEO of Kiadis Pharma. "The depth of his medical expertise in the field of bone marrow transplantations, his leadership worldwide in haplo-identical transplantation and his network with key opinion leaders in the field will greatly contribute to the success of our products and company".

"I am very excited to join Kiadis Pharma in the role of CMO. I look forward to participate in the development of its programs. I am particularly excited to w
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release fourth quarter ... on Monday, March 9th, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... GERMANTOWN, Maryland and HILDEN, Germany ... QGEN ; Frankfurt , Prime Standard:,QIA) today announced ... Institute,for Product Quality (ifp), pursuant to which QIAGEN has ... by the Berlin -based specialized,laboratory center for food ...
... ... and industry leaders from around the globe to discuss pain management, preclinical and clinical development ... ... Pain Therapeutics Summit , set to take place on October 4th-5th, 2010 in Philadelphia, has ...
... , May 25 Regado Biosciences, Inc., ... aptamers with active control agents, today announced issuance of ... new patent includes coverage for RB007, the modulator or ... REG1 and REG2 anticoagulation systems.  The allowed claims in ...
Cached Biology Technology:QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 2QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 3QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 4QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 5QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 6QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 7Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... may not be the only organisms endangered by some food ... health risks to humans who eat meat from chickens that ... the April 9 issue of Chemical & Engineering News, the ... Roxarsone, the most common arsenic-based additive used in chicken feed, ...
... As people age, they may have to exercise even harder ... suggestion of a report in the February issue of the ... signal that gives muscles a kind of metabolic boost in ... researchers found that so-called AMP-activated protein kinase (AMPK) slows down ...
... to repair the human body, replacing defective and worn ... the body does not always accept such substitutes seamlessly. ... simply changing the surface texture of implants can dramatically ... materials. , Two recent experiments have focused on ...
Cached Biology News:Power-boosting signal in muscle declines with age 2Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: